Eoin McDonnell

CEO at Tavros Therapeutics

Speaker

Eoin is the CEO and co-founder of Durham, NC-based Tavros Therapeutics, a precision oncology platform company. He is an expert in cancer biology with an emphasis on cellular signaling, epigenetics, cellular metabolism, and CRISPR/Cas9 genome editing tools. He has extensive experience in drug discovery in both startup biotech (Integrated Oncology Solutions and Element Genomics) and large pharma (Pfizer and UCB Pharma) settings. He earned his BA in Biology from Virginia Tech and a PhD in Molecular Cancer Biology from Duke University and was a postdoctoral fellow at Pfizer Oncology. He is an expert in developing cutting-edge functional genomic screens to identify novel drug targets, drug mechanism of action and complex cell signaling networks. At Element Genomics (acquired by UCB Pharma 2018) he contributed to significant advances in CRISPR/Cas9 phenotypic screening technology to identify novel drug targets. His passion is in discovering and novel cancer therapies using high-throughput screening technologies with an emphasis on understanding drug mechanisms of action, drug resistance and identifying tumor-specific vulnerabilities.